Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

3D Printing for Bio-Synthetic Biliary Stents
Boyer, Christen J., Boktor, Moheb , Samant, Hrishikesh , White, Luke A. , Wang, Yuping , Ballard, David H. , Huebert, Robert C. , Woerner, Jennifer E., Ghali, Ghali E., Alexander, J. Steven , Alexander, J Steven , Huebert, Robert , Ballard, David H

Mayo Clinic

Bioengineering | February 12, 2019 | Volume: 6 | Issue: 1 | Pages: 16

10.3390/bioengineering6010016 | PMID 30744131 Get It

Three-dimensional (3D) printing is an additive manufacturing method that holds great potential in a variety of future patient-specific medical technologies. This project validated a novel crosslinked polyvinyl alcohol (XL-PVA) 3D printed stent infused with collagen, human placental mesenchymal stem cells (PMSCs), and cholangiocytes. The biofabrication method in the present study examined 3D printing and collagen injection molding for rapid prototyping of customized living biliary stents with clinical applications in the setting of malignant and benign bile duct obstructions. XL-PVA stents showed hydrophilic swelling and addition of radiocontrast to the stent matrix improved radiographic opacity. Collagen loaded with PMSCs contracted tightly around hydrophilic stents and dense choloangiocyte coatings were verified through histology and fluorescence microscopy. It is anticipated that design elements used in these stents may enable appropriate stent placement, provide protection of the stent-stem cell matrix against bile constituents, and potentially limit biofilm development. Overall, this approach may allow physicians to create personalized bio-integrating stents for use in biliary procedures and lays a foundation for new patient-specific stent fabrication techniques.
Shoulder and Elbow Range of Motion Can Be Maintained in Major League Baseball Pitchers Over the Course of the Season, Regardless of Pitching Workload
Mcgraw, Michael, Vrla, Michael, Zajac, John M., Pearson, D., Sinatro, Alec A., Coleman, Struan H. , Wang, Dean , Camp, Christopher L. , Sinatro, Alec S., Dines, Joshua S.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | February 8, 2019 | Volume: 7 | Issue: 2 | Pages: No page available

10.1177/2325967118825066 | PMID 30800690 Get It

Background: Studies examining the evolution of shoulder and elbow range of motion (ROM) in baseball pitchers over a single season have yielded inconsistent results. Purpose: To evaluate shoulder and elbow ROM in Major League Baseball (MLB) pitchers over a single season and to assess for correlations between these changes and measures of a pitcher’s workload. Study Design: Case-control study; Level of evidence, 3. Methods: Bilateral shoulder ROM (internal rotation [IR], external rotation [ER], and total range of motion [TROM]) was assessed in 92 MLB pitchers pre- and postseason. Shoulder forward flexion (FF) was measured in 64 pitchers, horizontal adduction (HA) was measured in 87 pitchers, and elbow ROM was measured in 86 pitchers. Data collected included demographics (age, height, weight, and body mass index) and measures of workload for pitchers (pitches thrown, innings pitched, and mean fastball velocity). Pitchers were not specifically excluded if they had an injury during the season but had recovered and were actively pitching at the time of postseason measurements. The change in motion from pre- to postseason was measured and the associations with player demographics and workload were calculated by use of the Pearson correlation coefficient. Results: On average, pitchers demonstrated an increase in dominant shoulder ER from 118.8° to 125.4° ( P < .001) and TROM from 173.1° to 181.7° ( P < .001). HA was increased by an average of 15.7° ( P < .001). The average shoulder IR ( P = .189), FF ( P = .432), and elbow ROM (flexion, P = .549; extension, P = .185) remained similar over the span of the season. Average glenohumeral IR deficit did not increase. Pitcher demographics and measures of throwing workload (total pitches thrown, innings pitched, mean fastball velocity) were not significantly correlated with changes in shoulder or elbow ROM. Conclusion: Significant increases in dominant shoulder ER, TROM, and HA were identified in MLB pitchers over the course of a single baseball season. These ROM changes were not correlated with measures of pitching workload.
Spleen Tyrosine Kinase–Mediated Autophagy Is Required for Epithelial–Mesenchymal Plasticity and Metastasis in Breast Cancer
Shinde, Aparna , Hardy, Shana D., Akhand, Saeed Salehin , Anderson, Joshua C. , Khodadadi, Ryan B. , Brown, Wells S. , George, Jason T. , Liu, Sheng , Wan, Jun , Levine, Herbert , Krusemark, Casey J. , Wendt, Michael K. , Anderson, Joshua C , Khodadadi, Ryan B , Willey, Christopher D , Wendt, Michael K , Wan, Jun , Kim, Dong Wook , Jolly, Mohit Kumar , Wang, Wen‐Hung , Geahlen, Robert L.

Mayo Clinic

Cancer Research | February 7, 2019 | Volume: 79 | Issue: 8 | Pages: 1831-1843

10.1158/0008-5472.can-18-2636 | PMID 30733195 Get It

Abstract The ability of breast cancer cells to transiently transition between epithelial and mesenchymal states contributes to their metastatic potential. Therefore, driving tumor cells into a stable mesenchymal state, as opposed to complete tumor cell eradication, presents an opportunity to pharmacologically limit disease progression by promoting an asymptomatic state of dormancy. Here, we compare a reversible model of epithelial–mesenchymal transition (EMT) induced by TGFβ to a stable mesenchymal phenotype induced by chronic exposure to the ErbB kinase inhibitor lapatinib. Only cells capable of returning to an epithelial phenotype resulted in skeletal metastasis. Gene expression analyses of the two mesenchymal states indicated similar transition expression profiles. A potently downregulated gene in both datasets was spleen tyrosine kinase (SYK). In contrast to this similar diminution in mRNA, kinome analyses using a peptide array and DNA-conjugated peptide substrates showed a robust increase in SYK activity upon TGFβ-induced EMT only. SYK was present in cytoplasmic RNA processing depots known as P-bodies formed during the onset of EMT, and SYK activity was required for autophagy-mediated clearance of P-bodies during mesenchymal–epithelial transition (MET). Genetic knockout of autophagy-related 7 (ATG7) or pharmacologic inhibition of SYK activity with fostamatinib, a clinically approved inhibitor of SYK, prevented P-body clearance and MET, inhibiting metastatic tumor outgrowth. Overall, this study suggests assessment of SYK activity as a biomarker for metastatic disease and the use of fostamatinib as a means to stabilize the latency of disseminated tumor cells. Significance: These findings present inhibition of spleen tyrosine kinase as a therapeutic option to limit breast cancer metastasis by promoting systemic tumor dormancy. See related commentary by Farrington and Narla, p. 1756
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension
Mehanna, Mai , Wang, Zhiying , McDonough, Caitrin W. , Beitelshees, Amber L. , Gums, John G. , Chapman, Arlene B. , Schwartz, Gary L. , Bailey, Kent R. , Johnson, Julie A. , Beitelshees, Amber L. , Turner, Stephen T. , Gong, Yan , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

American Journal of Hypertension | February 6, 2019 | Volume: 32 | Issue: 7 | Pages: 668-675

10.1093/ajh/hpz022 | PMID 30753254 Get It

Abstract BACKGROUND Interindividual variability in blood pressure (BP) response to antihypertensives has been reported. Although plasma renin activity (PRA) is a potential biomarker for personalizing antihypertensive therapy in European American (EA) and African American (AA) hypertensives, clinical utility of PRA-guided prescribing is incompletely understood. METHODS Using systematic-phased approach, PRA’s clinical utility was assessed. After categorizing by baseline PRA, clinic systolic BP (SBP) responses to metoprolol and chlorthalidone were compared in 134 EAs and 102 AAs enrolled in the Pharmacogenomics Evaluation of Antihypertensive Responses-2 (PEAR-2) trial. Receiver operating characteristic (ROC) analysis was conducted in EAs. Data from PEAR-2 AAs were used to estimate an optimal PRA cut point using multivariable linear regression models. The derived cut point in AAs was tested in a meta-analysis of 2 independent AA cohorts, and its sensitivity and specificity were assessed. RESULTS EAs with PRA &lt; 0.65 ng/ml/hour had a greater decrease in SBP to chlorthalidone than metoprolol (by –15.9 mm Hg, adjusted P &lt; 0.0001), whereas those with PRA ≥ 0.65 ng/ml/hour had a greater decrease in SBP to metoprolol than chlorthalidone (by 3.3 mm Hg, adjusted P = 0.04). Area under ROC curve (0.69, P = 0.0001) showed that PRA can predict SBP response among EAs. However, we observed no association between PRA and SBP response in PEAR-2 AAs. Among independent AA cohorts, those with PRA ≥ 1.3 ng/ml/hour (PEAR-2-derived cut point) responded better to atenolol/candesartan than hydrochlorothiazide (meta-analysis P = 0.01). However, sensitivity of the derived cut point was 10%. CONCLUSIONS PRA at the previously established 0.60–0.65 ng/ml/hour cut point is an effective predictive biomarker of BP response in EAs. However, we were unable to identify PRA cut point that could be used to guide antihypertensive selection in AAs. TRIAL REGISTRATION NCT01203852, NCT00246519, NCT00005520.
Abstract A27: Diversity in multiple myeloma clinical trials
Duma, Narjust , Vélez, Miguel González , Vera-Aguilera, Jesús, Parrondo, Richardo, Adjei, Alex A. , Mariotti, Veronica , Paludo, Jonas , Wang, Yucai , Go, Ronald S.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 4, 2019 | Volume: 27 | Issue: 7_Supplement | Pages: A27-A27

10.1158/1538-7755.disp17-a27 Get It

Abstract Background: Multiple myeloma (MM) accounts for approximately 1% of all cancers and 10% of hematologic malignancies in the United States (U.S.). MM occurs in all races, but the incidence in African Americans is two to three times higher than in non-Hispanic whites. MM is also slightly more frequent in men than women (1.4:1). Many clinical trials lack appropriate representation of specific patient populations, limiting the generalizability of the evidence obtained. Therefore, we determined the representation of ethnic minorities, the elderly, and women in MM clinical trials. Methods: Enrollment data from all therapeutic trials reported as completed in clinicaltrial.gov from 2000 to 2016 were analyzed. Clinical trials including other hematologic malignancies and with recruitment outside of the U.S. were excluded. Enrollment fraction (EF) was defined as the number of enrollees divided by the 2013 SEER database MM complete prevalence. Chi-square test was used to estimate differences in categorical data. Results: Out of 177 MM clinical trials (CT), 78 (44%) reported ethnicity with a total of 12,055 enrollees. Regarding enrollees' ethnic composition, 84% were non-Hispanic White (NHW), 8.6% African American (AA), 2.8% Asian, 1.8% Hispanic, and 0.1% Native American/Alaskan Indian. Out of those 78 CT, 52 (66%) were phase II, 15 (19%) phase III, and 11 (14%) phase I. Most of the results were published from 2012 to 2016 (74%). Forty-six (59%) trials were sponsored by industry, 7 (9%) by NCI, and 25 (32%) were investigator initiated. Participation in CT varied significantly across ethnic groups, NHW were more likely to be enrolled in CT (EF of 0.23) than AA (EF of 0.08, p &lt; 0.0001) and Hispanics (EF of 0.05, p&lt; 0.0001). Males had a higher recruitment rate than females (58% vs. 42%), but this could be explained by the higher incidence of MM in males. Enrollees' median age was 62 years. Younger patients (&lt; 65 years) were more likely to be enrolled in CT than the elderly (66% vs. 34%, p&lt;0.0001). Industry-sponsored trials were less likely to recruit AA compared with investigator-initiated trials (7.6% vs. 12%, p&lt;0.01). Conclusions: Despite the higher incidence of MM in African Americans and the elderly, the former only represented 8.6% of the study participants and 66% of these were less than 65 years of age; therefore, we are lacking data in the tolerability of these new agents in our aging MM population. We also observed that industry studies were less likely to recruit AA patients. Collaborations between investigators, sponsors, and the community are necessary to increase our minority and elderly patients' access to clinical trials. Citation Format: Narjust Duma, Miguel Gonzalez Velez, Jesus Vera-Aguilera, Richardo Parrondo, Veronica Mariotti, Jonas Paludo, Yucai Wang, Ronald Go, Alex Adjei. Diversity in multiple myeloma clinical trials [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr A27.
Abstract A26: Representation of minorities, the elderly, and women in over 1000 clinical trials
Duma, Narjust , Vera-Aguilera, Jesús, Leventakos, Konstantinos , Mansfield, Aaron, Adjei, Alex A. , Wang, Yucai , Paludo, Jonas

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 4, 2019 | Volume: 27 | Issue: 7_Supplement | Pages: A26-A26

10.1158/1538-7755.disp17-a26 Get It

Abstract Background: Despite the importance of diversity while studying new drugs, many cancer clinical trials (CT) lack appropriate representation of specific patient populations, limiting the generalizability of the evidence obtained. Therefore, we determined the representation of ethnic minorities, the elderly, and women in cancer CT. Methods: Enrollment data from all therapeutic trials reported as completed in clinicaltrial.gov from 2003 to 2016 were analyzed. CT in rare cancers (&lt; 1% incidence) or with recruitment outside of the United States were excluded. Enrollment fraction (EF) was defined as the number of enrollees divided by the 2013 Surveillance Epidemiology and End Results (SEER) database cancer prevalence. Results: Out of 1,012 CT, 310 (31%) reported ethnicity with a total of 55,689 enrollees. 46,431 (83%) enrollees were non-Hispanic white, 3,270 (6%) African American, 2,982 (5.3%) Asian, 1,484 (2.6%) Hispanic, and 1,332 (2.4%) were classified as other. Participation in CT varied significantly across ethnic groups; non-Hispanic whites were more likely to be enrolled in CT (EF of 1.2%) than African Americans (EF of 0.7%, p &lt;0.001) and Hispanics (EF of 0.4%, p &lt;0.001). A decrease in African American (6% vs. 9.2%) and Hispanic (2.6% vs. 3.1%) enrollment was observed when compared with historical data from 1996 to 2002. Asians were well represented and their recruitment doubled over the past 14 years (2% vs. 5.3%). Hispanics were less represented in breast and prostate cancer CT, only contributing to 3% and 1.5% of the study population. African Americans were less represented in lung (5.4%) and renal cell carcinoma (3%) trials. Enrollees' median age was 60 years with 64% of patients &lt;65 years of age. Younger patients (&lt;65 years) were more likely to be enrolled in CT than the elderly (64% vs. 36%, p &lt; 0.001). Lower recruitment of female patients was observed in CT for melanoma (35%), lung (39%), and pancreatic cancer (40%). Conclusions: African Americans, Hispanics, and the elderly were less likely to be enrolled in CT. Comparing with historical data, we observed a decrease in minorities' recruitment over the past 14 years. This change could be attributed to the increased complexity of CT and mandatory molecular testing as many minorities lack access to institutions with genetic-testing capacity. Future trials should take extra measures to recruit participants who adequately represent the U.S. cancer population. Citation Format: Narjust Duma, Jesus Vera-Aguilera, Yucai Wang, Jonas Paludo, Konstantinos Leventakos, Aaron Mansfield, Alex Adjei. Representation of minorities, the elderly, and women in over 1000 clinical trials [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr A26.
Abstract A011: First-in-man clinical trial of intratumoral injection of Clostridiumnovyi-NT spores in patients with treatment-refractory advanced solid tumors: Safety, activity, and immune responses
Jankú, Filip , Gounder, Mrinal M. , Pezeshki, Abdul Mohammad, Piha‐Paul, Sarina A. , Raina, Anjali, Leontovich, Alexey A. , DeCrescenzo, Gary, Kreider, Brent L. , Tung, David, Varterasian, Mary , Zhang, Halle H., Khazaie, Khashayarsha , Murthy, Ravi , Wang‐Gillam, Andrea , Shepard, Dale R. , Hong, David S. , Piha-Paul, Sarina A

Mayo Clinic

Cancer Immunology Research | February 4, 2019 | Volume: 7 | Issue: 2_Supplement | Pages: A011-A011

10.1158/2326-6074.cricimteatiaacr18-a011 Get It

Abstract Bacteriolytic strategies offer unique advantages to combat a broad range of cancers often refractive to conventional chemotherapies and/or radiotherapies. C. novyi-NT is an attenuated strain of Clostridium novyi, a spore-forming, gram-positive, obligate anaerobe that lacks a lethal alpha- toxin, expressed by the parental strain. When administered intravenously or intratumorally with percutaneous injection, C. novyi-NT colonizes and replicates within the hypoxic region of the tumors, eliciting robust, tumor-confined cell lysis. In this first-in-man phase 1 study, patients with injectable treatment-refractory solid tumors received a single intratumoral injection of C. novyi-NT spores across 6 dose cohorts (spore concentrations of 104, 3x104, 105, 3x105, 106, 3x106) using a 3+3 trial design. The primary endpoints were to assess the safety profile, the dose limiting toxicity, and the maximum tolerated dose of C. novyi-NT. Key secondary endpoints included assessments of the preliminary antitumor activity of the injected tumor, an overall response evaluated by RECIST v. 1.1, and the host immune and inflammatory response to C. novyi-NT. Twenty-four patients were enrolled between November, 2013 and April, 2017. A single intratumoral injection of C. novyi-NT led to germination and resultant tumor lysis of injected tumor masses in 46% of patients across all dosing cohorts. The cohort 5 dose of 106 spores was defined as the maximum tolerated dose. Dose-limiting toxicities were grade 4 sepsis and grade 4 gas gangrene (n=1), all in patients with germination. In the 22 evaluable patients, 21 (95%) had stable disease (SD) as the best response for the injected lesion (tumor shrinkage of &gt; 10% was observed in 21% of patients) and 19 (86%) had overall SD as the best response per RECIST 1.1. C. novyi-NT injection resulted in transient serum cytokine responses consistent with inflammasome activity, activation of innate immunity, tissue remodeling, and angiogenesis. Tumor antigen specific ELISPOT assays pre- and post- treatment documented enhanced secretion of IFNγ and TNFα by circulating T-cells, indicating improved systemic tumor specific T-cell responses. Multiparametric in situ immunostaining of core biopsies suggested improved immune cell infiltration in metastatic lesions. These early signs of improved antitumor activity in patients with advanced solid tumors have encouraged a new trial of C. novyi-NT in combination with immune checkpoint inhibitors. Citation Format: Filip Janku, Mrinal Gounder, Abdul Mohammad Pezeshki, Ravi Murthy, Andrea Wang-Gillam, Dale Shepard, David S. Hong, Sarina A. Piha-Paul, Anjali Raina, Alexey A. Leontovich, Gary DeCrescenzo, Brent L. Kreider, David Tung, Mary Varterasian, Halle H. Zhang, Khashayarsha Khazaie. First-in-man clinical trial of intratumoral injection of Clostridiumnovyi-NT spores in patients with treatment-refractory advanced solid tumors: Safety, activity, and immune responses [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A011.
A Decision Analysis of Observation vs Immediate Reintervention for Asymptomatic Residual Fragments Less than 4 mm Following Ureteroscopic Lithotripsy
Ursiny, Michal, Yaghoubian, Alan J., Humphreys, Mitchell R. , Brotherhood, Hilary, Chew, Benjamin, Monga, Manoj, Krambeck, Amy E. , Charchenko, Cameron, Wang, An Qi, Sur, Roger L. , Miller, Nicole L. , Marien, Tracy , Chang, Yui-Hui H., Knudsen, Bodo E. , Lange, Dirk , Yong, Courtney , Matlaga, Brian R., Shah, Ojas , Pais, Vernon M., Lipkin, Michael E. , Eisner, Brian H. , Miller, Nicole L

Mayo Clinic

Urology Practice | February 4, 2019 | Volume: 6 | Issue: 5 | Pages: 294-299

10.1097/upj.0000000000000038 | PMID 37317352 Get It

A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer.
Benkhadra, Raed, Firwana, Belal , Mody, Kabir , Ahn, Daniel H. , Sonbol, Mohamad Bassam , Wang, Zhen , Kasi, Pashtoon Murtaza , Hubbard, Joleen M. , Murad, M. Hassan , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 619-619

10.1200/jco.2019.37.4_suppl.619 Get It

619 Background: Regorafenib (at a starting dose of 160 mg/day, rego 160), regorafenib (with a weekly dose escalation, rego 80+) and TAS-102, are suggested treatment options for refractory metastatic colorectal cancer (mCRC). We aimed to evaluate the comparative effectiveness evidence supporting these 3 strategies. Methods: We searched PubMed, Embase, and Cochrane CENTRAL, for randomized controlled trials evaluating TAS 102 or regorafenib in refractory mCRC patients who progressed on/intolerant of previous oxaliplatin, irinotecan, and fluoropyrimidine. Outcomes of interest included OS and PFS. The overall effect was pooled using the DerSimonian random effects model. We conducted network meta-analysis based on White’s multivariate meta-regression to pool evidence from direct and indirect comparisons. Results: Six trials (3 of regorafenib and 3 of TAS-102) at low risk of bias (2,445 patients) were included. Direct comparisons showed that Rego 160 and TAS-102 as monotherapy were superior to BSC in terms of PFS (Rego 160: HR = 0.4, CI 0.26 to 0.63; TAS-102: HR = 0.46, CI 0.40 to 0.52) and OS (Rego 160: HR = 0.67, CI 0.48 to 0.93; TAS-102: HR = 0.67, CI 0.57 to 0.80). Network analysis showed that there was no difference in PFS or OS between Rego 160 and TAS-102. Rego 80+ was superior to BSC in terms of OS (HR = 0.44, CI 0.23 to 0.84) and PFS (HR = 0.37, CI 0.21 to 0.66). There was a numerical advantage for Rego 80+ compared to TAS-102 and Rego 160 (see table). Conclusions: Regorafenib 160 and TAS-102 appear to have similar efficacy. Rego 80+ is shown to be superior to BSC. A trend for improved OS was observed with Rego 80+ versus Rego 160 or TAS 102. [Table: see text]
Endoscopic submucosal dissection using a novel endoscopic articulating knife for clinical staging of early esophageal neoplasia.
Priyan, Harshith, Wang, Kenneth T. , Genere, Juan Reyes

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 114-114

10.1200/jco.2019.37.4_suppl.114 Get It

114 Background: Clinical staging of early esophageal neoplasia traditionally involves histological confirmation and imaging with endoscopic ultrasound (EUS), CT, and PET which have low sensitivity and specificity for staging esophageal cancer (EC). Endoscopic submucosal dissection (ESD) therapy is traditionally used for treatment, but not diagnosis as it is felt to be technically challenging and have a high risk for complications. We applied a new articulating endoscopic knife that permits safe ESD (ESD-CC) to evaluate early neoplasia with potential curative resection. Methods: We performed a retrospective study of patients undergoing ESD to stage or treat suspected early EC (cT1-T2). Clinical stage was done by EUS, CT, and PET. Two expert GI pathologists reviewed all histology. Lesions were examined with high resolution white light endoscopy and narrow band imaging. ESD was done with 1:200,000 epinephrine and methylene blue dye injection for lifting and staining the submucosal space. A 5mm, scissors-like articulated knife was used to perform ESD and hemostasis. Complications during post-ESD observation or follow-up were recorded. Results: A total of 35 patients who underwent ESD-CC were included with median age 70 (IQR 12), 26 males (74%), and followed for a median 3.4 months (IQR 6.4). This group consisted of 32 potential adenocarcinomas and 3 squamous cell cancers. The clinical Pre-ESD diagnoses were cT1 EC (24, 69%) and suspected EC in Barrett’s esophagus (BE) (11, 31%). The cT1 EC cases had ESD staged at least T1b (5, 21%), T1a (11, 46%), EC in situ (1, 4%), and dysplastic BE (7, 29%). The suspected EC cases had ESD staged at least T1b (1, 9%), T1a (2, 18%), and DBE (8, 73%). ESD-CC up-staged 4 (11%), down-staged 10 (29%), and confirmed prior diagnosis in 21 (60%). No complications including bleeding, perforation, or stricture formation regardless of size of ESD, age of patient, or co-morbidities. Conclusions: Staging of early esophageal cancer can be improved using ESD with an articulating knife, without increase in complications. ESD may be used as a staging modality in early esophageal cancer.